Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Immix Biopharma, Inc. - Common Stock
(NQ:
IMMX
)
1.900
+0.010 (+0.53%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Immix Biopharma, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Why Immix Biopharma Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
May 22, 2023
Gainers SeqLL Inc. (NASDAQ: SQL) shares surged 61.1% to $0.54 in pre-market trading after dropping 14% on Friday. SeqLL recently posted a wider first-quarter loss.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
May 22, 2023
We're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about on Monday!
Via
InvestorPlace
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 26th Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)
May 04, 2023
•Updated clinical data for next-generation CAR-T NXC-201 in AL amyloidosis will be presented in Los Angeles May 16-20, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
What's Going On With Immix Biopharma Stock Today
May 03, 2023
Immix Biopharma Inc (NASDAQ: IMMX) announced early interim data from IMMINENT-01 Phase 1b/2a trial combining tissue-specific therapeutic IMX-110 with BeiGene Ltd (NYSE: BGNE) / Novartis AG'
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
May 03, 2023
Via
Benzinga
Immix Biopharma Announces Early Positive IMX-110 Interim Clinical Trial Data Demonstrating 100% Tumor Shrinkage in Advanced Metastatic Colorectal Cancer at the Lowest Dose of IMX-110 + BeiGene / Novartis Anti-PD-1 Antibody Tislelizumab
May 03, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
April 27, 2023
Via
Benzinga
Why NETGEAR Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
April 27, 2023
Gainers Evelo Biosciences, Inc. (NASDAQ: EVLO) jumped 147.9% to $0.2479. Evelo Biosciences shares dropped 33% on Wednesday after the company announced top-line data from the fourth cohort of its...
Via
Benzinga
Why Meta Platforms Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket
April 27, 2023
Gainers
Via
Benzinga
Nexcella, an Immix Biopharma subsidiary, Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in Light Chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris
April 26, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Nexcella, an Immix Biopharma subsidiary, announces poster presentation at the European Society for Blood and Marrow Transplantation 49th Annual Meeting
April 04, 2023
Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Paris, France 23-26 April 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Nexcella, an Immix Biopharma Subsidiary, Announces 2023 Haematologica Editorial Highlighting NXC-201 Efficacy In The Context of U.S. Food And Drug Administration Approved BCMA CAR T Cells
March 31, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Nexcella, an Immix Biopharma Subsidiary, Announces New Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in AL Amyloidosis Patients + Additional Positive Multiple Myeloma Safety Data Demonstrating NXC-201 Outpatient CAR-T Treatment
March 23, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank
March 10, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
ImmixBio to Discuss Recent Positive NXC-201 Clinical Data in AL Amyloidosis and Multiple Myeloma at the 35th Annual Roth Conference on March 14
March 06, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
February 23, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
February 22, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 22, 2023
February 22, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
February 22, 2023
Via
Benzinga
Immix Biopharma Subsidiary Nexcella Enters into U.S. GMP Manufacturing Agreement to Expand Ongoing NXC-201 Phase 1b/2 Clinical Trial to the U.S.
February 15, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Subsidiary Nexcella, Inc. Presents 42-Patient Interim Data, with 90% Overall Response Rate in Relapsed or Refractory Multiple Myeloma at NXC-201 Therapeutic Dose from its Phase 1 Expansion Trial at the 5th European CAR T-cell Meeting
February 09, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
February 07, 2023
Via
Benzinga
Immix Biopharma Announces Dosing of First 2 Patients in its IMX-110 + BeiGene/Novartis anti-PD-1 Tislelizumab Phase 1b/2a Combination Clinical Trial in Patients with Advanced Cancer
February 07, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
EXCLUSIVE: Top 10 Most Searched Tickers On Benzinga Pro In January: Where Do SPY, Tesla, Apple And Ford Rank?
February 05, 2023
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.
Via
Benzinga
Immix Biopharma Doses Additional Patients in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial
January 13, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
January 06, 2023
Via
Benzinga
Immix Biopharma Subsidiary Nexcella, Inc. Announces Additional Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in Relapsed/Refractory AL Amyloidosis Patients, Duration of Response Not Yet Reached
January 06, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Nexcella, Inc., a subsidiary of Immix Biopharma, announces poster presentation at the European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting
December 28, 2022
Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Rotterdam, Netherlands February 9-11, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
December 22, 2022
Via
Benzinga
Immix Biopharma Announces 16th Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial
December 20, 2022
From
Immix Biopharma, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.